La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novonesis Bilan de santé

Santé financière contrôle des critères 5/6

Novozymes possède un total de capitaux propres de DKK14.4B et une dette totale de DKK7.4B, ce qui porte son ratio d'endettement à 51.6%. Son actif total et son passif total sont DKK28.4B et de DKK14.0B. L'EBIT de Novozymes est DKK4.5B ce qui fait que son ratio de couverture des intérêts 53.8. Elle dispose de liquidités et de placements à court terme de DKK1.1B.

Informations clés

18.1%

Ratio d'endettement

€1.99b

Dette

Ratio de couverture des intérêts	15.7x
Argent liquide	€260.80m
Fonds propres	€11.01b
Total du passif	€4.25b
Total des actifs	€15.25b

Mises à jour récentes de la santé financière

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NSIS B ( DKK9.5B ) dépassent ses passifs à court terme ( DKK7.3B ).

Passif à long terme: Les actifs à court terme de NSIS B ( €1.8B ) ne couvrent pas ses passifs à long terme ( €2.6B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de NSIS B ( 15.7% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de NSIS B a été réduit de 36.2% à 18.1% au cours des 5 dernières années.

Couverture de la dette: La dette de NSIS B est bien couverte par le flux de trésorerie opérationnel ( 56% ).

Couverture des intérêts: Les paiements d'intérêts de NSIS B sur sa dette sont bien couverts par l'EBIT ( 53.8 x couverture).

Novonesis Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Recent updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly